Efficacy of LCAR-T2C CAR-T cells
BM2L201905
Phase 1 small_molecule terminated
Quick answer
Efficacy of LCAR-T2C CAR-T cells for CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia) is a Phase 1 program (small_molecule) at Legend Biotech Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Legend Biotech Corp
- Indication
- CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated